FDA, Merck and Vioxx: Putting Patient Safety First?
There was no video broadcast for this event.
Graham, M.D., M.P.H
Associate Director for ScienceOffice of Drug Safety, Center for Drug Evaluation and Research, Department of Health and Human Services, Food and Drug AdministrationWashington , DC
Adjunct Clinical Professor of Medicine, Division of Gastroenterology and HepatologyDepartment of Medicine, Stanford UniversityStanford , CA
Pstay, M.D., Ph.D.
Professor, Medicine & EpidemiologyUniversity of Washington, Cardiovascular Health Research UnitSeattle , WA
Acting Director, Office of New Drugs, Center for Drug Evaluation and ResearchDepartment of Health and Human Services, Food and Drug AdministrationWashington , DC
Chairman, President & Chief Executive OfficerMerck & Co.Whitehouse Station , NJ
How do I submit a statement for the record?
Any individual or organization wanting to present their views for inclusion in the hearing record should submit in a Word document, a single-spaced statement, not exceeding 10 pages in length. No other file type will be accepted for inclusion. Title and date of the hearing, and the full name and address of the individual or organization must appear on the first page of the statement. Statements must be received no later than two weeks following the conclusion of the hearing.
Statements can be emailed to:
Statements should be mailed (not faxed) to:
Senate Committee on Finance
Attn. Editorial and Document Section
Dirksen Senate Office Bldg.
Washington, DC 20510-6200